VLA1553, commercially known as Ixchiq, has received USFDA clearance and will be launched in India — which has seen high number of chikungunya cases — after ‘regulatory talks with DCGI’.
Trial of live-attenuated vaccine VLA1553 was conducted in US, with high seroprotection rates observed in participants up to 180 days after vaccination. Study published in 'The Lancet'.
Researchers from Chulalongkorn University in Thailand find that chikungunya strain identified in Thailand has mutations that originated in India and Bangladesh
As social media debated whether audiences were consuming Pujarini Pradhan as a symbol, The Juggernaut turned her into a story that could circulate globally, with or without her participation.
Regulator seeks feedback on allowing firms to repurchase shares via exchanges after tax changes, as markets reel from war-led selloff and foreign outflows.
China patiently invested capital, skill and technology in coal gasification. Unlike it, we won’t move from words to action. As crude prices decline, we lose interest.
COMMENTS